DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

company name or ticker

August 7th Options Now Available For Sarepta Therapeutics (SRPT)

Hot-Handed Billionaire Investors Crushing the S&P This Year, Buying These Stocks: AIG, MU, JBLU, SPY

Is This Heavily Shorted Biotech Stock a Good Contrarian Buy?

Short-sellers have piled into Adaptimmune Therapeutics and MannKind Corp. this year. Could these two biotechs represent good contrarian buys for the long-term investor?

BioMarin Slips After Baird Breaks From Pack With Downgrade

SunTrust's 5 Biotech Picks For The Next 6 Months

BioMarin Seeks EU Approval for DMD Drug Drisapersen - Analyst Blog

Stocks To Watch in Orphan Drugs

Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with upcoming catalysts that could propel their shares higher.

Sarepta Therapeutics (SRPT) Showing Signs Of Perilous Reversal Today

An Undervalued Biotech Is Testing the Cure for Cancer Now, and Chen Lin Wants In

Here's What Caused Sarepta Therapeutics Inc. to More Than Double in May

Sarepta Therapeutics rockets higher by triple-digits in May following an update on the development of its lead drug eteplirsen. Find out what announcement had Wall Street and investors clamoring to buy its stock and whether or not it's still worth buying.
See More Articles...